Safety assessment of poly I:C in NZB/NZW mice (38565).
The present report confirms the findings by Steinberg et al. (9) that repeated intraperitoneal injections of poly I:C (3 mug/g, three times per wk, 40-52 doses) enhanced the incidence and severity of glomerular lesions that occur spontaneously in NZG/NZW mice and also increased the development of circulating antibody against nucleic acids. This effect was minimal when only six intraperitoneal doses were given in 1 mug/g amount at weekly intervals. Intranasal administration of poly I:C (0.2 mug/g, three times per wk, 40 doses) or six doses of the drug (1 mug/g weekly) caused no apparent potentiation of glomerular response. ICR/Ha mice, which do not suffer from the spontaneously occurring disease, were uneffected by poly I:C treatment except for occasional development of antibody against poly I:C or DNA.
D000281:Administration, Intranasal; D000818:Animals; D000906:Antibodies / Q000032:analysis*; D004247:DNA / Q000276:immunology*; D004353:Drug Evaluation, Preclinical; D005260:Female; D007274:Injections, Intraperitoneal; D007678:Kidney Glomerulus / Q000187:drug effects*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008814:Mice, Inbred NZB; D011070:Poly I-C / Q000008:administration & dosage / Q000009:adverse effects*; D012313:RNA / Q000276:immunology*
D000906:Antibodies; D012313:RNA; D004247:DNA; D011070:Poly I-C